Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines

Shcherbik, Svetlana; Carney, Paul; Pearce, Nicholas; Stevens, James; Dugan, Vivien G.; Wentworth, David E.; Bousse, Tatiana

doi:10.1016/j.virol.2018.07.005

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines

Published Date:

July 12 2018

Publisher's site:

http://dx.doi.org/10.1016/j.virol.2018.07.005 New Site Icon

Source:

Virology. 522:65-72

Language:

English

[PDF-964.72 KB]

Details:

Alternative Title:

Virology

Personal Author:

Shcherbik, Svetlana ; Carney, Paul ; Pearce, Nicholas ; Stevens, James ; Dugan, Vivien G. ; ... More ▼

Description:

Cold adapted influenza virus A/Leningrad/134/17/57 (H2N2) is a reliable master donor virus (Len/17-MDV) for preparing live attenuated influenza vaccines (LAIV). LAIVs are 6:2 reasortants that contain 6 segments of Len/17-MDV and the hemagglutinin (HA) and neuraminidase (NA) of contemporary circulating influenza A viruses. The problem with the classical reassortment procedure used to generate LAIVs is that there is limited selection pressure against NA of the Len/17-MDV resulting in 7:1 reassortants with desired HA only, which are not suitable LAIVs. The monoclonal antibodies (mAb) directed against the N2 of Len/17-MDV were generated. 10C4-8E7 mAb inhibits cell-to-cell spread of viruses containing the Len/17-MDV N2, but not viruses with the related N2 from contemporary H3N2 viruses. 10C4-8E7 antibody specifically inhibited the Len/17-MDV replication in vitro and in ovo but didn't inhibit replication of H3N2 or H1N1pdm09 reassortants. Our data demonstrate that addition of 10C4-8E7 in the classical reassortment improves efficiency of LAIV production.

Subject:

[+]

Pubmed ID:

30014859

Pubmed Central ID:

PMC6498426

Document Type:

Journal Article

Funding:

CC999999/Intramural CDC HHS/United States

Collection(s):

CDC Public Access

Main Document Checksum:

[+]

Supporting Files:

	nihms-1024869-f0005.gif	image/gif
	nihms-1024869-f0005.jpg	image/jpeg
	nihms-1024869-f0006.gif	image/gif
	nihms-1024869-f0006.jpg	image/jpeg
	nihms-1024869.nxml	text/xml
	nihms-1024869-f0001.gif	image/gif
	nihms-1024869-f0001.jpg	image/jpeg
	nihms-1024869-f0002.gif	image/gif
	nihms-1024869-f0002.jpg	image/jpeg
	nihms-1024869-f0003.gif	image/gif
	nihms-1024869-f0003.jpg	image/jpeg
	nihms-1024869-f0004.gif	image/gif
	nihms-1024869-f0004.jpg	image/jpeg

No Related Documents.

You May Also Like:

Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses

Personal Author:

Shcherbik, Svetlana; Pearce, Nicholas; Kiseleva, Irina; Larionova, Natalie; Rudenko, Larisa; Xu, Xiyan; Wentworth, David E.; Bousse, Tatiana;

Published Date:

Oct 28 2015

Source:

J Virol Methods. 227:33-39.

Description:

Cold-adapted influenza strains A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69, originally developed in Russia, have been reliable master donors of attenuation for preparing live attenuated influenza vaccines (LAIV). The classical strategy for generati...

File Type:

[PDF - 706.71 KB]
Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation

Personal Author:

Shcherbik, Svetlana; Pearce, Nicholas; Balish, Amanda; Jones, Joyce; Thor, Sharmi; Davis, Charles Todd; Pearce, Melissa; Tumpey, Terrence; Cureton, David; Chen, Li-Mei; Villanueva, Julie; Bousse, Tatiana L.;

Published Date:

Sep 25 2015

Source:

PLoS One. 10(9).

Description:

BackgroundAvian influenza A (H7N9) virus has emerged recently and continues to cause severe disease with a high mortality rate in humans prompting the development of candidate vaccine viruses. Live attenuated influenza vaccines (LAIV) are 6:2 reassor...

File Type:

[PDF - 383.47 KB]
Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production

Personal Author:

Shcherbik, Svetlana; Sergent, Sheila B.; Davis, William G.; Shu, Bo; Barnes, John; Kiseleva, Irina; Larionova, Natalie; Klimov, Alexander; Bousse, Tatiana;

Published Date:

Sep 18 2013

Source:

J Virol Methods. 195:18-25.

Description:

Development and improvement of quality control tests for live attenuated vaccines are a high priority because of safety concerns. Live attenuated influenza vaccine (LAIV) viruses are 6:2 reassortants containing the hemagglutinin (HA) and neuraminidas...

File Type:

[PDF - 474.65 KB]
Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model

Personal Author:

Korenkov, Daniil A.; Laurie, Karen L.; Reading, Patrick C.; Carolan, Louise A.; Chan, Kok Fei; Isakova-Sivak, Irina I.; Smolonogina, Tatiana A.; Subbarao, Kanta; Barr, Ian G.; Villanueva, Julie; Shcherbik, Svetlana; Bousse, Tatiana; Rudenko, Larisa G.;

Published Date:

June 19 2018

Source:

Infect Genet Evol. 64:95-104

Description:

Live attenuated influenza vaccines (LAIVs) are promising tools for the induction of broad protection from influenza due to their ability to stimulate cross-reactive T cells against influenza pathogens. One of the major targets for cytotoxic T-cell im...

File Type:

[PDF - 1.41 MB]
Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model

Personal Author:

Isakova-Sivak, Irina; Korenkov, Daniil; Smolonogina, Tatiana; Tretiak, Tatiana; Donina, Svetlana; Rekstin, Andrey; Naykhin, Anatoly; Shcherbik, Svetlana; Pearce, Nicholas; Chen, Li-Mei; Bousse, Tatiana; Rudenko, Larisa;

Published Date:

Nov 06 2016

Source:

Virology. 500:209-217.

Description:

This study sought to improve an existing live attenuated influenza vaccine (LAIV) by including nucleoprotein (NP) from wild-type virus rather than master donor virus (MDV). H7N9 LAIV reassortants with 6:2 (NP from MDV) and 5:3 (NP from wild-type viru...

File Type:

[PDF - 3.42 MB]